26-11-2025 16:55 via drugs.com

Early Use of Higher-Efficacy Therapies Recommended for Moderate-to-Severe Crohn Disease

WEDNESDAY, Nov. 26, 2025-- Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), according to a living clinical practice guideline issued by the American Gastroenterology...

Persistent Thyroid Hormone Imbalance During Pregnancy Tied to Heightened Autism Risk in Offspring

Eight Trajectories of Long COVID Identified in U.S. Adults

Less Than One in Five Who Are Eligible Undergo Lung Cancer Screening

Obstructive Sleep Apnea Appears to Be Risk Factor for Development of Parkinson Disease

Grant Funding Disruptions Affect One in 30 Clinical Trials

First-Trimester Ultrasounds Detect 40 Percent of Anomalies

Exome Sequencing Can ID Those Who Are Genotype-Positive for Familial Hypercholesterolemia

Radiofrequency Coagulation Effective for Recurrent Anterior Epistaxis

Adenotonsillectomy Safe in Children With Down Syndrome, Other Genetic Syndromes

Cannabis Use Disorder Adversely Affects Inpatient Asthma Outcomes

One Week Less on Social Media Linked to Better Mental Health

Your Brain Changes in Stages as You Age, Study Finds

Some Suicide Victims Show No Typical Warning Signs, Study Finds

ByHeart Formula Faces Lawsuits After Babies Sickened With Botulism

Desktop versie

Early Use of Higher-Efficacy Therapies Recommended for Moderate-to-Severe Crohn Disease

Pharmaceutical news